|
ICARE: Interagency Collaborative to Advance Research in Epilepsy
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA, OS
|
NINDS, FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NIBIB, NICHD, NIDA, NIGMS, NIMH, NINR
|
The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the NIH ICs involved in epilepsy-related research, as well as across HHS and other Federal agencies and multiple epilepsy research and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals.
|
|
Image-guided Interventional Therapeutics
|
Research Initiative
|
FDA
|
CC, NCI
|
This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the FDA Center for Devices and Radiological Health''s preclinical review of device applications while meeting the primary research goal of optimizing image guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies.
|
|
Implementation Barriers to Screening, Brief Intervention and Referral to Treatment (SBIRT) in Federally Qualified Health Centers (FQHCs)
|
Research Initiative
|
HRSA
|
NIDA
|
This project will examine the use of SBIRT for substance use disorders in Federally Qualified Health Centers (FQHCs) to identify barriers to implementation and effective strategies for overcoming these challenges. The purpose of the project is to inform policy makers and providers regarding best practices and implementation strategies to overcome identified barriers. There has yet to be a systematic evaluation of SBIRT implementation challenges in FQHCs. With joint participation from the National Institute on Drug Abuse (NIDA) and the Health Resources and Services Administration (HRSA), this project will investigate SBIRT implementation at FQHCs to learn about best practices and implementation strategies that have been critical to supporting implementation of SBIRT, as well as the challenges that present barriers to implementation. Findings from this project may help inform efforts to increase SBIRT uptake among FQHCs and other primary care settings.
|
|
Improving Community Health through Land Reuse
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR
|
NIEHS
|
Workgroup to discuss and provide input on Brownfields land reuse activities. NIEHS participates in this workgroup and were involved in the planning and writing of an online book being produced by the Agency for Toxic Substances and Disease Registry.
|
|
Improving Technical Standards and Molecular Tools for Probiotics Research and Development
|
Research Initiative
|
FDA
|
NCCAM
|
In 2008, the USDA Agricultural Service initiated a Memorandum of Understanding (MOU) with NCCAM to exchange expertise in technology development and partner research initiatives to advance the field of probiotic biology and role in human health. The MOU consists of a five year plan defining common mission goals; expected benefits from the exchange of research expertise and resources; and demonstration projects based on NIH/NCCAM funded U01 cooperative agreements. The long-term goal of the MOU is to develop trans-agency networked initiatives. In 2012, the unique resources of the USDA Agricultural Research Service and the Human Microbiome Project investigators were successfully implemented as a parallel comparative biotechnologies validation and standardization prototype with targeted molecular approaches.
|
|
IMS Health Contract
|
Research Initiative
|
CDC
|
NIDA
|
NIDA and the HHS Assistant Secretary for Planning and Evaluation (ASPE) are working collaboratively to analyze prescribing trends of opioid analgesics and stimulants under the terms of a Third Party Agreement (TPA) between IMS Health, NIDA, and ASPE.
|
|
Industry Wide Exposure Assessment Study of Workers to Carbon Nanotubes and Nanofibers
|
Research Initiative
|
CDC
|
NIEHS
|
This study will measure workplace exposures to Carbon nanotubes and Carbon nanofibers among a representative sample of US manufacturers and downstream users.
|
|
Influenza (Flu) Risk Management Meeting (FRMM)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Influenza (Flu) Risk Management Meeting (FRMM) meetings provide members with a venue to discuss issues relating to the U.S. Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v.
|
|
Influenza Vaccine Manufacturing Improvement Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Influenza Vaccine Manufacturing Improvement Group aims to optimize donor strains, improve sterility assays, and develop alternative potency assays.
|
|
Inter-Agency Committee on Drug Control (ICDC)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS, SAMHSA
|
NIDA
|
The Inter-Agency Committee on Drug Control (ICDC) serves to facilitate communication between government agencies, including NIDA, FDA, DEA, and SAMHSA regarding drug control policies and initiatives.
|